Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

sed into formal preclinical studies including IND-enabling toxicology studies. This program will lead to the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration(FDA) in the fourth quarter of 2008. The preclinical development program has already been considered by the FDA in pre-IND reviews, including a face-to-face meeting with FDA reviewers last month.

"The accumulated data for CYT387 clearly indicates that this compound has an excellent potency and safety profile for the treatment of patients with MPDs. We are aggressively progressing this compound through formal preclinical studies with the aim of beginning clinical trials by the end of this year," said Mr. Andrew Macdonald, CEO of Cytopia.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.

CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structural biology program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including the treatment of certain cancers, particularly lymphomas and solid tumors where JAK2 has been shown to be up-regulated, and for cardiovascular diseases such as pulmonary hypertension.

About Cytopia

Cytopia Ltd is an Australian biotechnology company
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Calif., April 24, 2012  A dose of 10 milligrams (mg) ... fermented soy germ-based nutritional supplement is as effective as a ... significantly and is even more effective for relieving muscle and ... women published in the June Journal of Women,s Health ...
... April 24, 2012  The Intellectual Property & Science ... to support R&D pharmaceutical leaders with a new ... use by AstraZeneca executives. The rich visualization dashboard ... , the company,s flagship life sciences platform, ...
Cached Medicine Technology:Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 2Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 3Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 4Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 5Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 6Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 7Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 8Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders 2
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... in the United States have nearly doubled since 1988, suggests ... Health, with obesity apparently to blame for the surge. The ... not hit all groups equally, with alarming increases in diabetes ... research reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... a decades-old medical mystery and in the process have found ... kill about 1.5 million people a year. The researchers say they ... that has been in use for more than 50 years ... it is to the microbes it attacks. , A report ...
(Date:4/15/2014)... California, San Diego School of Medicine have identified a mechanism ... liver disease and why the virus is able to persist ... pathogen, which infects an estimated 200 million people worldwide, attacks ... the cell,s innate ability to fight infection. It does this ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... China Healthcare Acquisition Corp. (the "Company") (NYSE Alternext ... meeting held today, March 5, 2009, its stockholders voted ... early distribution of the Company,s trust fund for the ... March 5, 2009. Today,s vote had the automatic effect ...
... FRANKLIN, Tenn., March 5 /PRNewswire/ -- ... services, today announced details for the release of its financial ... plans to issue its earnings release for the fourth quarter ... March 25, 2009, and will host a conference call on ...
... not getting services they need to prevent another attack, ... After suffering a stroke, the chances of having another ... aren,t getting the interventions they need to reduce that ... smoking cessation and exercise, and medical treatments, such as ...
... the Aspen Health Stewardship Project will unveil a new ... support of a roadmap for making smart, sustainable improvements ... which includes patient groups, and health employer and provider ... America by adopting a set of core principles to ...
... Re-enrollment OpportunitiesHARRISBURG, Pa., March 5 Insurance ... laid off from a job that offered health insurance ... provide them with relief on premiums and that now ... information."I want to let Pennsylvanians know that additional help ...
... it has received a $76 million grant from the Bill ... and young child nutrition in developing countries in Africa and ... to increase rates of exclusive breastfeeding and improve complementary feeding ... children die and millions more are permanently disabled as a ...
Cached Medicine News:Health News:China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date 2Health News:Second Stroke Prevention Efforts Found Wanting 2Health News:Second Stroke Prevention Efforts Found Wanting 3Health News:Aspen Institute to Introduce Roadmap for Responsible Health Care Reform, New Coalition To Call For Sustainable Improvements 2Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2Health News:AED Receives Gates Foundation Grant to Improve Nutrition and Reduce Deaths Among Young Children in Developing Countries 2
...
...
... biomechanical properties influence the results and ... and may hold clues to diagnosing ... assessing the biomechanical properties of corneal ... practitioners and researchers to measuring purely ...
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
Medicine Products: